Chiesi Pharmaceuticals LLS as an AIPM member company recognizes their responsibility to society. On this basis, Chiesi Pharmaceuticals LLS accepts and undertakes fulfill the requirements of the AIPM Code of Practice and to follow it not only in letter but also in spirit.
Chiesi Pharmaceuticals LLS as an AIPM member company should strive to observe the rules of fair competition in their activities and to refrain from harming the image, position, or economic interests of competitors through any improper conduct, including but not limited to, inappropriate advertising or any other unfair methods of promoting pharmaceutical products.
Chiesi Pharmaceuticals LLS as an AIPM member company shall make efforts to promote the Code in order for it to be correctly understood and applied both by their own employees and by other representatives of the pharmaceutical community of the Russian Federation.
Chiesi Pharmaceuticals LLS as an AIPM member company seek to further develop the standards of the Code, among other things, by suggesting relevant updates, additions, and modifications to its requirements. Pharmaceutical products are socially significant products and public health depends on their properties. The pharmaceutical industry is responsible for providing society as a whole and the medical and pharmaceutical communities in particular with objective information on pharmaceutical products. Moreover, it is essential to take into account the risk to which public health may be exposed in the absence of necessary regulation of the procedures for the disclosure of such information. Aware of the increased social responsibility borne by the manufacturers of pharmaceutical products, representatives of the pharmaceutical industry of developed countries began to adopt standards regulating their marketing and other activities as early as in the middle of the last century. In 1981, the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), which at that time united 50 national associations, adopted the IFPMA Code of Pharmaceutical Marketing Practices, the observance of which from 1988 became a condition of membership for national associations and, accordingly, a requirement for their member companies. Many IFMPA member associations have developed and adopted their own codes taking into account national conditions but not contradicting the general principles set forth in the IFPMA Code. The Association of International Pharmaceutical Manufacturers (AIPM), a non-commercial IFPMA member organization acting on the territory of the Russian Federation, which currently represents the interests of 55 of the world’s leading pharmaceutical companies, adopted the AIPM Code of Marketing Practices in 1998. Due to the lack of detailed special requirements in Russian legislation, the document played a positive role during in the introduction of standards for the civilized promotion of pharmaceutical products on the Russian pharmaceutical market. Remaining dedicated to its commitment to high ethical standards, AIPM became a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) in 2012. AIPM fully shares EFPIA position that there is a growing expectation that interactions between pharmaceutical companies and society are not only conducted with integrity but are also transparent.